- Diagnostics
- 2 min read
Roche Diagnostics India launches NT-proBNP test for diabetes patients at risk of CVD
The NT-proBNP test on the cobas h 232 system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions.
Diabetes is associated with significant morbidity and mortality. Patients living with diabetes are at a higher risk of developing CVD: up to 46 per cent of diabetic patients will develop CVD in their lifetime, which is responsible for about 50 per cent of mortality in T2D patients. Moreover, statistics indicate a staggering 30 per cent of diabetic patients develop HF during their lifetime. Individuals with T2D and HF face up to an 8x increased risk of death compared to those without HF. Despite the number, approximately 80 per cent of HF cases are only diagnosed following acute hospitalisation, despite patients experiencing symptoms up to five years prior.
The challenge lies in the non-specific symptoms of HF, which often remain undetected until advanced stages. The NT-proBNP test on the cobas h 232 system facilitates early detection (screening) and intervention, enabling clinicians to identify high-risk T2D patients and initiate timely treatment discussions.
Dr Sanjay Kalra, Chief Endocrinologist, Bharti Hospital, Karnal, India, said the incorporation of the NT-proBNP test extension onto convenient point-of-care platforms signifies a notable stride in diabetes care. This innovative biomarker, when integrated into primary care settings, enables us to proactively assess heart failure risks in patients with T2D, thereby fostering improved outcomes and bolstering patient well-being.
Dr Rishubh Gupta, Managing Director, Roche Diagnostics India & Neighbouring Markets, said, “The extended claim on our NT-proBNP test now available on our point-of-care system underscores our mission to empower clinicians with cutting-edge tools for early diagnosis and personalised patient care.”
The NT-proBNP test for diabetes at point-of-care marks a significant milestone in the journey towards proactive and personalised healthcare for T2D patients.
COMMENTS
All Comments
By commenting, you agree to the Prohibited Content Policy
PostBy commenting, you agree to the Prohibited Content Policy
PostFind this Comment Offensive?
Choose your reason below and click on the submit button. This will alert our moderators to take actions